MetLife, Inc. (MET) Stock Price & Analysis
MetLife, Inc. (MET) closed at USD 103.57 on Thursday, October 22, 2026, up 1.36% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 102.18; the Oct 22, 2026 session ranged USD 101.21–103.65 on volume of 3,505,871 shares. Market capitalization is $65.82B, with a 52-week range of USD 67.33–103.65 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MET.md
Key facts (MET)
- Last four reported quarters (through Jun 30, 2026): revenue $79.4B, net income $3.63B (4.6% margin) (SEC filings).
- Valuation: P/E 18.2x (avg 20.3x at the last 3 fiscal year-ends), EV/EBITDA 7.9x, net cash $13.1B.
- 2 of 80 tracked superinvestors hold MET (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 2.11 on a 1–5 scale) (18 analysts), mean target USD 107.63 (range 84–119).
- Total return with dividends: 1Y +36.3% vs S&P 500 +14.9%; 5Y +82.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 2.77, revenue estimate $20.0B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MET)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $68.7B | $68.8B | $66.9B | $71.0B | $77.1B | $79.4B |
| Operating income | — | $5.98B | $5.72B | $6.00B | $6.14B | $6.56B |
| Net income | $6.86B | $5.28B | $1.58B | $4.43B | $3.38B | $3.63B |
| EPS (diluted) | $7.65 | $6.30 | $1.81 | $5.94 | $4.71 | — |
| Operating margin | — | 8.7% | 8.6% | 8.4% | 8.0% | 8.3% |
| Net margin | 10.0% | 7.7% | 2.4% | 6.2% | 4.4% | 4.6% |
| Revenue growth | +1.3% | +0.1% | -2.7% | +6.1% | +8.6% | — |
| Cash + short-term investments | $27.2B | $25.1B | $26.7B | $25.2B | $25.6B | — |
| Total debt | $13.9B | $14.6B | $15.5B | $15.1B | $14.5B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MET)
P/E 18.2x · P/S 0.8x · EV/EBITDA 7.9x · EV/Sales 0.7x · P/B 2.4x · Earnings yield 5.51% · Dividend yield (paid, TTM) 2.29% · Buyback yield (TTM) 3.71% · Net cash $13.1B · EV $52.7B
P/E at fiscal year-ends: Dec 2025 15.7x, Dec 2024 13.2x, Dec 2023 31.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (MET)
2 of 80 tracked investors hold MET. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Richard Pzena | Pzena Investment Management | 2.76% | $942M | Reduced -1.5% |
| Dodge & Cox Funds | Dodge & Cox | 2.15% | $4.10B | Reduced -5.3% |
Analysts (MET)
Consensus Buy (mean 2.11 on a 1–5 scale), 18 analysts; mean target USD 107.63 (low 84, high 119).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Target raised | Buy | $110 → $114 |
| 2026-10-15 | JP Morgan | Target raised | Overweight | $108 → $110 |
| 2026-10-12 | Wells Fargo | Target raised | Overweight | $109 → $110 |
| 2026-10-07 | Mizuho | Target lowered | Outperform | $112 → $109 |
| 2026-10-07 | Barclays | Target raised | Overweight | $97 → $111 |
| 2026-10-06 | UBS | Target raised | Buy | $105 → $110 |
| 2026-10-05 | TD Cowen | Target raised | Buy | $105 → $110 |
| 2026-09-22 | Piper Sandler | Upgrade | Neutral → Overweight | $99 → $110 |
| 2026-08-24 | Morgan Stanley | Target raised | Overweight | $103 → $111 |
| 2026-08-19 | Wells Fargo | Target raised | Overweight | $101 → $109 |
| 2026-08-11 | JP Morgan | Target raised | Overweight | $106 → $108 |
| 2026-08-11 | Keefe, Bruyette & Woods | Target raised | Outperform | $105 → $108 |
Total return (dividends reinvested) (MET)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +36.3% | +82.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +36.4% | +12.8% |
| Volatility (annualized) | 23.3% | 25.5% |
| Max drawdown | -17.5% (Dec 2025→Mar 2026) | -33.6% (Nov 2022→May 2023) |
MET revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Group Benefits | $6.87B | 35.9% | +1.1% |
| RIS | $3.99B | 20.8% | +12.4% |
| Asia | $3.07B | 16.0% | +5.9% |
| Latin America | $2.49B | 13.0% | +19.6% |
| EMEA | $873.0M | 4.6% | +11.9% |
| MIM | $319.0M | 1.7% | +33.5% |
| Total revenue | $19.15B | 100% | — |
MET revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Feebasedinvestmentmanagementservices | $186.0M | 1.0% | +95.8% |
| Prepaidlegalplansandadministrativeonlycontracts | $176.0M | 0.9% | +11.4% |
| Vision Fee For Service Arrangements | $144.0M | 0.8% | +8.3% |
| Intersegment Non Elimination | $133.0M | 0.7% | +2.3% |
| Otherrevenuefromservicecontractsfromcustomers | $101.0M | 0.5% | -9.0% |
| Administrative Service | $82.0M | 0.4% | +12.3% |
| Distribution Service | $35.0M | 0.2% | +2.9% |
| Total revenue | $19.15B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name MET in their SEC reports
| Relationship to MET | Company | Filing | Sentence |
|---|---|---|---|
| partner | Brighthouse Financial, Inc. (BHF) | 10-K Feb 24, 2026 | “Under the tax separation agreement with MetLife, Inc. (the "Tax Separation Agreement"), MetLife is generally obligated to indemnify us against such taxes if the failure to qualify for tax-free treatment results from, among other things, any action or inaction that is within MetLife's control.” |
MET company outlook (results filed Aug 5, 2026)
- “Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.”
- “(6) Assumes a 21% tax rate.”
- “(7) The total U.S. statutory adjusted capital, on a National Association of Insurance Commissioners basis, is expected to be approximately $16.4 billion at June 30, 2026, up 1% from $16.2 billion at March 31, 2026.”
Quoted word-for-word from the SEC 8-K results press release.
MET analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.77 | $2.53 | +9.5% | $19.97B | 16 |
| Next quarter (ends Dec 2026) | $2.62 | $2.57 | +1.8% | $20.46B | 13 |
| Current fiscal year (ends Dec 2026) | $10.22 | $9.85 | +3.7% | $79.68B | 17 |
| Next fiscal year (ends Dec 2027) | $11.16 | $10.99 | +1.6% | $82.96B | 17 |
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 103.57 |
|---|---|
| Change | ▲ 1.36% (up) |
| Previous Close | USD 102.18 |
| Open | USD 101.59 |
| Day Range | USD 101.21 – 103.65 |
| 52-Week Range | USD 67.33 – 103.65 |
| Volume | 3,505,871 shares |
| Market Cap | $65.82B |
| Exchange | NYQ |
Technical Analysis (MET)
Nexqual's technical model rates MET "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.26 (neutral) |
| vs SMA50 | Above (USD 97.23) |
| MACD | 1.52 (positive) |
Analyst Ratings (MET)
Wall Street analysts rate MET "Buy" based on 18 analysts, with a mean price target of USD 107.63 (range USD 84–119), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 107.63 |
| High Target | USD 119 |
| Low Target | USD 84 |
| Buy / Hold / Sell | 13 / 4 / 1 |
Earnings (MET)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 2.77 |
| Revenue Estimate | $19.97B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.43 vs est 2.29 ▲ beat |
| 2026-03-31 | USD 2.42 vs est 2.27 ▲ beat |
| 2025-12-31 | USD 2.49 vs est 2.34 ▲ beat |
| 2025-09-30 | USD 2.37 vs est 2.32 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (MET)
| Total Revenue | $79.40B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.50% |
| Gross Margin | +23.95% |
| Operating Margin | +5.52% |
| Profit Margin | +4.57% |
| ROE | +13.09% |
| Debt / Equity | 1.8 |
| Current Ratio | 2.03 |
| Total Cash | $27.32B |
| Total Debt | $50.31B |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (MET)
Nexqual rates MetLife, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 24%, operating 6% (last 12 months) |
| Balance Sheet | Weak — $27.3B cash and investments vs $14.2B debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — Operating cash flow $17.1B (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — ROE 13%, ROA 0.5% |
Ownership (MET)
| Insider Ownership | +16.35% |
|---|---|
| Institutional Ownership | +78.41% |
| Shares Outstanding | 635.48M |
| Float | 531.23M |
| Short % of Float | +1.77% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (MET)
MetLife, Inc. is led by Michel Abbas Khalaf, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| CEO, President & Director | Michel Abbas Khalaf |
|---|---|
| Executive VP, CFO & Head of Investment Management | John Dennis McCallion |
| Regional President of U.S. Business & Head of MetLife Holdings | Ramy Tadros |
| Executive VP & Chief Marketing Officer | Michael Roberts |
Major Backers & Investors (MET)
Notable institutional backers of MetLife, Inc. include Dodge & Cox Inc., Price (T.Rowe) Associates Inc, Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 7.53% |
| Price (T.Rowe) Associates Inc | 3.31% |
| Morgan Stanley | 1.95% |
| Pzena Investment Management LLC | 1.73% |
| Fidelity | 1.09% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.18% |
| BlackRock | 8.05% |
| State Street | 3.94% |
| Geode Capital | 2.07% |
| Dimensional Fund Advisors | 1.12% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
From MetLife, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Outside of the U.S., our subsidiaries are subject to various data protection regimes, including the General Data Protection Regulation (EU) 2016/679 ("GDPR"), which imposes strict requirements for controllers and processors of personal data and on transfers of personal data outside of the EEA to countries which have not been deemed "adequate" by the European Commission.
- We distribute our products and services primarily through our proprietary institutional client sales force and institutional client service teams for each major asset strategy.
- We have built a leading position in the U.S. group insurance market through long-standing relationships with many of the largest employers in the U.S.
- For retrospective experience rating, we evaluate past experience to determine our cost of providing insurance for the customer in light of any features that allow us to recoup certain losses or distribute certain gains back to the policyholder based on prior years' experience.
Partnerships
- Our RIS segment, based in the U.S., provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in Laws or Regulation, or in Supervisory and Enforcement Policies, May Reduce Our Profitability, Limit Our Growth, or Otherwise Adversely Affect Us
- We may incur costs to comply with laws and regulations and changes to or interpretations of these laws and regulations may increase our expenses and regulatory capital charges.
- Laws, regulations or regulatory actions may limit or change the type, amount or structure of compensation or benefits we offer our employees or others, or may limit or ban the use of non-competition agreements, which may harm our ability to compete in recruiting and retaining key personnel. We may also fail to fulfill our fiduciary or other client and benefit-related obligations completely.
- Compliance with solvency standards or financial condition regulations may increase our capital and reserve requirements, risk management costs, and reporting costs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AFL | AFLAC Incorporated | USD 123.27 | ▲ 2.6% |
| MFC | Manulife Financial Corporation | USD 45.62 | ▲ 0.8% |
| PRU | Prudential Financial, Inc. | USD 118.17 | ▲ 2.92% |
| PUK | Prudential Public Limited Compa | USD 24.01 | ▼ 1.6% |
| UNM | Unum Group | USD 93.75 | ▲ 0.04% |
| GL | Globe Life Inc. | USD 168.41 | ▼ 0.71% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt